The Europe Arthritic Therapeutic Market would witness market growth of 4.8% CAGR during the forecast period (2023-2030).
The Germany market dominated the Europe Arthritic Therapeutic Market, by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $7,462.7 Million by 2030. The UK market is exhibiting a CAGR of 3.9% during (2023 - 2030). Additionally, The France market would experience a CAGR of 5.5% during (2023 - 2030).
Patient preferences, beliefs, and experiences play a significant role in shaping their adoption. Factors such as treatment efficacy, route of administration, frequency of dosing, potential side effects, and cost impact patients’ willingness to adhere to prescribed therapies. Establishing collaborative treatment plans that align with patient’s values, preferences, and lifestyle factors promotes shared decision-making between healthcare providers and patients.
Arthritic therapeutics are primarily utilized to manage the symptoms associated with arthritis, including pain, inflammation, stiffness, and swelling. Pharmacological interventions such as nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, analgesics, and disease-modifying antirheumatic drugs (DMARDs) help alleviate pain and reduce inflammation, improving mobility and enhancing the quality of life for patients with arthritis.
The aging population in Europe is accompanied by increased healthcare expenditure, as older adults require more medical services, treatments, and long-term care for chronic conditions, including arthritis. The aging population in Europe fuels demand for senior care services, specialized clinics, and multidisciplinary care teams focused on managing age-related health conditions, including arthritis. Thus, all these factors will uplift the regional market’s expansion in the coming years.
Based on Application, the market is segmented into Rheumatoid Arthritis, Psoriatic Arthritis, Osteoarthritis, Ankylosing Spondylitis and Others. Based on Product Type, the market is segmented into Non-steroidal Anti-inflammatory Drugs (NSAIDs), Disease Modified Anti-rheumatoid Drugs (DMARDs), Biologics, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The Germany market dominated the Europe Arthritic Therapeutic Market, by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $7,462.7 Million by 2030. The UK market is exhibiting a CAGR of 3.9% during (2023 - 2030). Additionally, The France market would experience a CAGR of 5.5% during (2023 - 2030).
Patient preferences, beliefs, and experiences play a significant role in shaping their adoption. Factors such as treatment efficacy, route of administration, frequency of dosing, potential side effects, and cost impact patients’ willingness to adhere to prescribed therapies. Establishing collaborative treatment plans that align with patient’s values, preferences, and lifestyle factors promotes shared decision-making between healthcare providers and patients.
Arthritic therapeutics are primarily utilized to manage the symptoms associated with arthritis, including pain, inflammation, stiffness, and swelling. Pharmacological interventions such as nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, analgesics, and disease-modifying antirheumatic drugs (DMARDs) help alleviate pain and reduce inflammation, improving mobility and enhancing the quality of life for patients with arthritis.
The aging population in Europe is accompanied by increased healthcare expenditure, as older adults require more medical services, treatments, and long-term care for chronic conditions, including arthritis. The aging population in Europe fuels demand for senior care services, specialized clinics, and multidisciplinary care teams focused on managing age-related health conditions, including arthritis. Thus, all these factors will uplift the regional market’s expansion in the coming years.
Based on Application, the market is segmented into Rheumatoid Arthritis, Psoriatic Arthritis, Osteoarthritis, Ankylosing Spondylitis and Others. Based on Product Type, the market is segmented into Non-steroidal Anti-inflammatory Drugs (NSAIDs), Disease Modified Anti-rheumatoid Drugs (DMARDs), Biologics, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
List of Key Companies Profiled
- AbbVie, Inc.
- Pfizer, Inc.
- Amgen, Inc.
- Novartis AG
- F.Hoffmann-La Roche Ltd.
- Viatris, Inc.
- Bausch Health Companies, Inc.
- Sanofi S.A.
- Merck & Co., Inc.
- Bristol-Myers Squibb Company
Market Report Segmentation
By Application- Rheumatoid Arthritis
- Psoriatic Arthritis
- Osteoarthritis
- Ankylosing Spondylitis
- Others
- Non-steroidal Anti-inflammatory Drugs (NSAIDs)
- Disease Modified Anti-rheumatoid Drugs (DMARDs)
- Biologics
- Others
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 5. Europe Arthritic Therapeutic Market, by Application
Chapter 6. Europe Arthritic Therapeutic Market, by Product Type
Chapter 7. Europe Arthritic Therapeutic Market, by Country
Chapter 8. Company Profiles
Companies Mentioned
- AbbVie, Inc.
- Pfizer, Inc.
- Amgen, Inc.
- Novartis AG
- F. Hoffmann-La Roche Ltd.
- Viatris, Inc.
- Bausch Health Companies, Inc.
- Sanofi S.A.
- Merck & Co., Inc.
- Bristol-Myers Squibb Company
Methodology
LOADING...
